India's battle against cervical malignancies is entering a decisive phase. Although vaccinations protect future generations, they do not safeguard adult women currently at risk. Consequently, implementing organized cervical cancer screening is essential for mortality reduction. Leading experts advocate for molecular screening to achieve elimination.

The Clinical Transition to HPV DNA Testing

For decades, visual inspection with acetic acid and cytology have been the mainstay of screening in low-resource settings. However, these traditional methods are often limited by low sensitivity, high operator dependence, and poor clinical reproducibility. Therefore, the World Health Organization strongly recommends human papillomavirus (HPV) DNA testing as the primary screening tool. Molecular testing offers unparalleled analytical sensitivity, enabling clinicians to identify high-risk viral strains before pre-cancerous lesions develop. Consequently, integrating HPV DNA testing into the national framework represents a critical advancement in cervical cancer screening. Furthermore, this objective laboratory method completely eliminates provider subjectivity, ensuring highly consistent results across diverse clinical settings. By adopting molecular diagnostics, healthcare systems can safely extend screening intervals because of the test's high accuracy. In addition, this clinical shift allows clinicians to focus resources on true-positive cases, optimizing patient care. Standardizing HPV DNA testing is therefore a vital prerequisite for any successful national cervical cancer elimination strategy. Finally, comprehensive clinical training must accompany this transition to ensure that healthcare providers interpret molecular results correctly.

Limitations of Visual Inspection in Cervical Cancer Screening

While visual inspection with acetic acid played an important historical role, it is no longer suitable for disease elimination. Specifically, visual inspection is highly subjective and depends heavily on the training and experience of individual providers. Consequently, it suffers from a high false-positive rate, which triggers unnecessary referrals to tertiary care facilities. These redundant referrals place an unsustainable burden on oncology departments while causing severe, avoidable anxiety for patients. In contrast, molecular HPV testing offers an objective, standardized result that removes operator bias entirely from the equation. Therefore, leading gynaecologists argue that visual inspection must be viewed as a temporary bridge rather than the destination. Transitioning to validated molecular assays is necessary to establish an equitable diagnostic standard across urban and rural India. By implementing this critical clinical shift, policymakers can ensure that screening results are consistently reliable and clinically actionable. This major shift is crucial because relying on suboptimal tests hinders our ability to identify high-risk patients early. Ultimately, India must invest in validated, high-quality diagnostics to protect women from the consequences of inaccurate test results.

Balancing Clinical Sensitivity and Specificity

In public health discussions, the focus is often placed on maximizing clinical sensitivity to detect many cases. However, clinical specificity deserves equal attention, particularly in resource-constrained environments where diagnostic infrastructure is limited. Every false-positive result triggers redundant colposcopies, biopsies, and specialist consultations, which overwhelm tertiary referral centers. Therefore, the primary objective of a population-based screening program should be to identify patients who genuinely require treatment. Fortunately, emerging evidence demonstrates that targeted HPV genotype assays can maintain high clinical sensitivity while improving specificity. By focusing specifically on the most oncogenic viral strains, clinicians can avoid over-diagnosing transient infections that resolve spontaneously. Consequently, this targeted approach prevents unnecessary surgical procedures and reduces the heavy clinical burden on the healthcare system. Balancing sensitivity and specificity is absolutely essential for building a sustainable national screening framework that commands public trust. This critical balance ensures that diagnostic accuracy goes hand-in-hand with efficient resource utilization across all clinical tiers.

Point-of-Care Assays and Reducing Loss to Follow-up

Patient compliance and retention represent major challenges in conventional cervical cancer screening programs across developing nations. Historically, rural women have had to travel long distances and lose wages to visit clinics. If the screening process requires multiple visits, many patients simply do not return for follow-up. Consequently, the clinical benefits of screening are lost, and patients remain at risk of advanced malignancies. To overcome this critical barrier, the implementation of validated point-of-care HPV DNA tests is highly recommended. These rapid diagnostic platforms deliver reliable molecular results within an hour, enabling immediate same-visit clinical decisions. For instance, the indigenous Truenat HPV-HR Plus platform combines high analytical sensitivity with excellent operational simplicity. By facilitating same-day triage, these near-patient technologies dramatically minimize loss to follow-up among high-risk patients. Furthermore, integrating digital connectivity and standardized workflows ensures that patient data is seamlessly tracked and managed. In addition, point-of-care diagnostics reduce the overall cost of patient navigation and clinical care. Ultimately, same-day testing makes cervical screening more accessible, patient-friendly, and highly effective for underserved populations.

Procurement Standards and Clinical Governance

As indigenous molecular platforms enter the medical market, policymakers must not base procurement decisions solely on cost. A screening test is not a mere commodity; rather, it is a critical clinical investment in women's health. Therefore, new diagnostic assays must undergo rigorous multicentric clinical validation before being integrated into national programs. Affordability must always go hand-in-hand with robust clinical evidence and continuous post-market surveillance. For example, local manufacturers must demonstrate that their assays meet strict international performance standards for diagnostic accuracy. By enforcing these rigorous quality benchmarks, the government can protect the population from suboptimal, unvalidated diagnostic tests. Furthermore, establishing clear clinical governance, including training for healthcare workers, is essential for program success. Sustaining this high level of clinical integrity is crucial for building public trust in the screening system. When healthcare providers are confident in the screening tools, they can deliver better counseling and guidance. Ultimately, robust clinical validation ensures that our resources are spent on reliable diagnostic solutions that save lives. This disciplined approach will accelerate our transition to an organized screening program that yields measurable health benefits.

Frequently Asked Questions

Q1: Why is HPV DNA testing preferred over conventional cytology or VIA for cervical cancer screening?

HPV DNA testing is preferred because it offers significantly higher clinical sensitivity and objectivity than cytology or visual inspection. While VIA is subjective and prone to high false-positive rates, molecular assays identify high-risk viral DNA reliably. This prevents missed pre-cancerous lesions and allows for safely extended screening intervals, making it highly effective for national elimination.

Q2: How do rapid point-of-care HPV tests help reduce patient loss to follow-up?

Traditional screening often requires multiple clinic visits to receive results and undergo triage, leading to high drop-out rates among rural women. Point-of-care tests, such as the validated Truenat HPV-HR Plus platform, deliver accurate molecular results in under an hour. This enables same-day counseling and clinical decision-making, ensuring patients are not lost during the process.

Q3: Why should public procurement of diagnostic tests not be based solely on price?

Procuring diagnostic tests solely on cost can compromise outcomes if assays lack validation. To ensure program success, molecular diagnostics must undergo rigorous multicentric clinical validation and health technology assessments. Affordability must be balanced with robust clinical evidence and strict quality assurance to ensure that the public health system utilizes highly reliable, validated tests.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. India Must Shift to HPV DNA-Based Screening to Eliminate Cervical Cancer, SaysDr Neerja Bhatla - ETHealthworld


2. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions. Geneva: WHO; 2026.


3. Joseph AN, Bhatla N. Population-based HPV testing. Natl Med J India 2021;34:36-37.